During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
More top news
Hundreds of surgeries face closure if older family doctors are not retained, the Royal College of GPs has warned.
The Duke of Cambridge said his children were beginning a "lifetime of friendship" with Canada as they began their tour of the country.
When and where are they on, and how do they work?